Application Nr Approved Date Route Status External Links
NDA205649 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Xigduo Xr Is Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus. Dapagliflozin Is Indicated To Reduce The Risk Of Hospitalization For Heart Failure In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease (Cvd) Or Multiple Cardiovascular (Cv) Risk Factors. Limitations Of Use Xigduo Xr Is Not Recommended For Patients With Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis. Xigduo Xr Is A Combination Of Dapagliflozin, A Sodium-Glucose Cotransporter 2 (Sglt2) Inhibitor, And Metformin, A Biguanide, Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus. (1) Dapagliflozin Is Indicated In Adults With Type 2 Diabetes Mellitus To Reduce The Risk Of Hospitalization For Heart Failure In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease Or Multiple Cardiovascular Risk Factors. (1) Limitations Of Use : • Not For Treatment Of Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments